# EDGAR Filing Document

**Accession Number:** 0001680200
**File Stem:** 0001104659-26-023732
**Filing Date:** 2026-3
**Character Count:** 26195
**Document Hash:** 610d3dd9cdb9c9a6d940d875d3cf500e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-023732.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001104659-26-023732

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92668
- **FILM NUMBER:** 26724076

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sofinnova Venture Partners X, L.P.
- **CENTRAL INDEX KEY:** 0001680200

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-681-8420

**MAIL ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

## Ex-99.A

<u>exhibit A</u>

<u>Agreement of Joint Filing</u>

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Aerovate Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

Date: February 3, 2023

---

| | |
|:---|:---|
| SOFINNOVA VENTURE PARTNERS X, L.P., a Delaware Limited Partnership | SOFINNOVA VENTURE PARTNERS X, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership |
| Its: | General Partner |
| By: | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership | SOFINNOVA MANAGEMENT X, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company | SOFINNOVA MANAGEMENT X-A, L.L.C., a Delaware Limited Liability Company |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| DR. JAMES I. HEALY | DR. JAMES I. HEALY |
| DR. MAHA KATABI | DR. MAHA KATABI |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |

---

## Ex-99.B

<u>exhibit B</u>

**<u>Power of Attorney</u>**

Nathalie Auber has signed this Schedule 13D as Attorney-In-Fact. Note that copies of the applicable Power of Attorney are already on file with the appropriate agencies.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Jade Biosciences, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**008064206**

*(CUSIP Number)*

**Nathalie Auber**<br>Sofinnova Investments, Inc.<br>3000 Sand Hill Road, Bldg 3, Suite 150<br>Menlo Park CA 94025<br>(650) 681-8420

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/28/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **008064206** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Venture Partners X, L.P. ("SVP X")** | Name of reporting person<br>**Sofinnova Venture Partners X, L.P. ("SVP X")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: 107,391 shares, except that Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting power, Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting power, and Dr. James I. Healy ("Healy") and Dr. Maha Katabi ("Katabi"), the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 107,391 shares, except that SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **008064206** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management X, L.P. ("SM X LP")** | Name of reporting person<br>**Sofinnova Management X, L.P. ("SM X LP")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **008064206** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management X-A, L.L.C. ("SM X LLC")** | Name of reporting person<br>**Sofinnova Management X-A, L.L.C. ("SM X LLC")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to Row 7: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM X LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **008064206** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**107391.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 8: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Healy, a managing member of SM X LLC, may be deemed to have shared voting power to vote these shares.

Note to Row 10: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Healy, a managing member of SM X LLC, may be deemed to have shared dispositive power over these shares.

| **CUSIP No.** | **008064206** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**107391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**107391.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | Aggregate amount beneficially owned by each reporting person<br>**107391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 8: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole voting power, SM X LLC, the general partner of SM X LP, may be deemed to have sole voting power, and Katabi, a managing member of SM X LLC, may be deemed to have shared voting power to vote these shares.

Note to Row 10: 107,391 shares, all of which are owned directly by SVP X.  SM X LP, the general partner of SVP X, may be deemed to have sole dispositive power, SM X LLC, the general partner of SM X LP, may be deemed to have sole dispositive power, and Katabi, a managing member of SM X LLC, may be deemed to have shared dispositive power over these shares.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Jade Biosciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453

This Amendment No. 3 ("Amendment No. 3") amends and restates the Statement on Schedule 13D that was initially filed on July 13, 2021 and amended on February 6, 2023 and February 20, 2024 (as amended, the "Original Schedule 13D").  This Amendment No. 3 relates to the beneficial ownership of Common Stock, par value $0.0001 per share ("Common Stock") of Jade Biosciences, Inc. (previously Aerovate Therapeutics, Inc.), a Nevada corporation (the "Issuer") by Sofinnova Venture Partners X, L.P., a Delaware limited partnership ("SVP X"), Sofinnova Management X, L.P., a Delaware limited partnership ("SM X LP"), Sofinnova Management X-A, L.L.C., a Delaware limited liability company ("SM X LLC"), Dr. James I. Healy ("Healy"), and Dr. Maha Katabi ("Katabi" and collectively with SVP X, SM X LP, SM X LLC, and Healy, the "Reporting Persons").  This Amendment No. 3 is being filed to update the aggregate percentage of the class of securities of the Issuer owned by the Reporting Persons as a result of the closing of the merger of Jade Biosciences, Inc. and Aerovate Therapeutics, Inc. on April 28, 2025 (the "Merger").  Immediately prior to the consummation of the Merger, the Issuer effected a 1-for-35 reverse stock split (the "Reverse Stock Split").  As a result of the Merger and the Reverse Stock Split, the Reporting Persons ceased to own more than five percent (5%) of the outstanding shares of the Issuer's Common Stock.

(a)          The class of equity securities to which this statement relates is the Common Stock of the Issuer.

(b)          The Issuer's principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts 02453.

**Item 4. Purpose of Transaction**

The Reporting Persons hold their securities of the Issuer for investment purposes.  Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners.  Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments.  Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 32,626,730 shares of Common Stock outstanding as of September 30, 2025, as reported in the Issuer's Form 424(b)(3) filed with the Securities and Exchange Commission on December 30, 2025 (File No. 333-292369).

**(b)**
Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

**(c)**
Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

SVP X and Katabi have agreed that, without the prior written consent of Jefferies LLC and Cowen and Company, LLC, on behalf of the Issuer's underwriters, they will not, subject to limited exceptions, during the period ending 180 days after the date set forth on the Prospectus offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, whether now owned or hereinafter acquired, owned directly (including holding as a custodian) or with respect to which they have beneficial ownership within the rules and regulations of the Securities and Exchange Commission.  Such Lock-Up Agreement is more fully described in the Prospectus and was filed as Exhibit A to Exhibit 1.1 to the Issuer's Amendment No. 3 to Form S-1 Registration Statement (File No. 333-256949), and such description is incorporated herein by reference.

SVP X is a party to an Investors' Rights Agreement among the Issuer, SVP X and other shareholders.  Subject to the terms of such Investors' Rights Agreement, SVP X can demand that the Issuer file a registration statement or request that its Common Stock be covered by a registration statement that the Issuer is otherwise filing under certain specified circumstances.  Such Investors' Rights Agreement dated as of August 5, 2020 is more fully described in the Prospectus and was filed as Exhibit 4.2 to the Issuer's Form S-1 Registration Statement (File No. 333-256949), and such description is incorporated herein by reference.

Katabi, in her capacity as a director of the Issuer, along with the other directors of the Issuer, entered into an Indemnification Agreement with the Issuer.  Such Indemnification Agreement is more fully described in the Prospectus and the form of such Indemnification Agreement was filed as Exhibit 10.5 to the Issuer's Amendment No. 1 to Form S-1 Registration Statement (File No. 333-256949), and such description is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Venture Partners X, L.P. ("SVP X")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management X, L.P. ("SM X LP")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management X-A, L.L.C. ("SM X LLC")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. James I. Healy ("Healy")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. Maha Katabi ("Katabi")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 03/05/2026